Hims & Hers Health Inc.’s shares jumped Tuesday after it said it was broadening its weight-loss offerings, adding access to brand name shots like Zepbound after previously focusing on cheaper ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 index. Investor excitement about news of a fresh product launch the ...

Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide — the active ingredient in weight-loss drug ...

Hims & Hers Health HIMS-10.35%decrease; red down pointing triangle said it is expanding its weight-loss offerings with the addition of Eli Lilly LLY-3.56%decrease; red down pointing triangle & Co ...

In a statement posted to the newsroom of Hims & Hers (HIMS), Craig Primack stated in part: “In my experience of treating thousands of people, lasting results come from focusing on the individual ...

While there's still plenty of work to be done, Hims is one of many such companies that's helping to expand healthcare options, by opening the conversation around men's health, in particular.

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that left investors unimpressed. Shares of the digital healthcare platform ...

Hims & Hers Health announces that it's expanding access to personalized weight loss care. Hims & Hers will offer both Lilly's Zepbound and Mounjaro on its platform, as well as generic versions of ...

Shares of Hims & Hers Health (NYSE: HIMS) surged on Tuesday, closing the session up 5.25% after having been up by as much as 14% earlier. That jump came as the S&P 500 and Nasdaq Composite showed ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform. The treatments will each cost $ ...